100 Days Mission Mpox Clock: Day 100
Today marks Day 100 since WHO declared mpox a public health emergency of international concern (PHEIC) on 14th August 2024. This update provides a comprehensive review of progress achieved in diagnostic, therapeutic, and vaccine (DTV) availability over the past 100 days and outlines priority actions for accelerating response in the next 100 days.
This analysis supports ongoing work by 100 Days Mission partners and has been developed in consultation with implementing organizations. These updates are intended to support the work of partners and key initiatives. While our regular 15-day reporting cycle concludes with this review, we will continue to provide major updates when significant developments occur in the mpox response.
Accompanying this update is an op-ed in The Guardian by IPPS Chair Dr Mona Nemer. This provides further perspective on where we are 100 days after the mpox PHEIC declaration, what we could have done differently, and how leaders can commit to ensuring tests, treatments and vaccines reach those who most need them.
Previous updates documenting the journey to day 100:
- Day 75 update (major)
- Day 60 update (minor)
- Day 45 update (major)
- Day 30 update (minor)
- Day 15 update (major)
- Day 0 statement
Note that throughout this period, we refined our tracking metrics to better capture progress and incorporate feedback. Where relevant, we will retrospectively standardise data to current metrics. However, the overall picture of DTV status remains unchanged.
For data updates or feedback, please contact info@ippsecretariat.org.
100 Days Mpox Timeline
Supporting Resources on Mpox Response
- WHO lists Abbott Molecular Inc.’s Alinity M MPXV assay under Emergency Use Listing
- WHO lists Roche Molecular System’s cobas MPXV qualitative assay under Emergency Use Listing
- WHO lists Cepheid’s Xpert Mpox molecular test under Emergency Use Listing
- WHO lists KM Biologic Co.’s LC16m8 vaccine under Emergency Use ListingWHO prequalifies Bavarian Nordic’s MVA-BN vaccine
- WHO grants prequalification for age-extension of Bavarian Nordic’s MVA-BN vaccine for use in adolescents (12-17 years)
- INTREPID Alliance has published their third edition of the Antiviral Clinical and Preclinical Development Landscape, which now includes mpox
- 100,000 doses of MVA-BN have been delivered to DRC
- 265,000 doses of MVA-BN have been delivered to DRC
- 5,420 doses of MVA-BN have been delivered to Rwanda
- Vaccination begins in DRCVaccination begins in Rwanda
- New Outbreaks Page on the Pandemic PACT Programme Website includes a dedicated Mpox Outbreak Page which offer real-time tracking of research funding and regularly updated outbreak summary reports
- Africa CDC published Mpox Continental Preparedness and Response Plan for Africa
- SIGA secures license to novel poxvirus mAbs
- FIND’s newsletter details the mpox diagnostic landscape, including evaluations of 10 promising point-of-care tests